The latest price target for Vaxcyte (NASDAQ:PCVX) was reported by Cantor Fitzgerald on April 22, 2025. The analyst firm set a price target for $0.00 expecting PCVX to fall to within 12 months (a possible -100.00% downside). 26 analyst firms have reported ratings in the last year.

The latest analyst rating for Vaxcyte (NASDAQ:PCVX) was provided by Cantor Fitzgerald, and Vaxcyte initiated their overweight rating.

There is no last upgrade for Vaxcyte

There is no last downgrade for Vaxcyte.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vaxcyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vaxcyte was filed on April 22, 2025 so you should expect the next rating to be made available sometime around April 22, 2026.

While ratings are subjective and will change, the latest Vaxcyte (PCVX) rating was a initiated with a price target of $0.00 to $0.00. The current price Vaxcyte (PCVX) is trading at is $34.28, which is out of the analyst’s predicted range.